Adding onto my post about Murcidencel being ideal for oncologist considering Off-Label use and why insurance coverage will be welcomed because it saves money overall.
This from the JAMA Oncology Journal excerpt (page E7) on Murcidencel supports that.
The benign safety profile observed with DCVax-L can enable treatment of patients vulnerable to adverse events. Furthermore, it avoids the need (and cost) for other treatments to manage side effects.